Cognition Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a $3.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ram Selvaraju has given his Buy rating due to a combination of factors related to the promising developments surrounding Cognition Therapeutics’ lead candidate, zervimesine. The company has made significant progress in its Phase 2 ‘START’ study, which is nearing full enrollment. This study is crucial as it evaluates the efficacy and tolerability of zervimesine in individuals with mild cognitive impairment and early Alzheimer’s disease, with results expected to provide valuable insights into the drug’s potential.
Furthermore, Cognition Therapeutics has aligned with the FDA on the design of a Phase 3 program for zervimesine, indicating regulatory confidence in the drug’s development pathway. The company is also advancing an expanded access program for dementia with Lewy bodies, where zervimesine has already demonstrated substantial clinical benefits. These developments, combined with the drug’s ability to significantly slow cognitive decline and reduce caregiver distress, underpin Selvaraju’s optimistic outlook and reaffirmation of a Buy rating.